Mandate

VINGE ADVISES FORTUM with SALE OF Fortum Distribution

March 16, 2015

Fortum and a consortium consisting of the First Swedish National Pension Fund (12.5%), the Third Swedish National Pension Fund (20%) and Folksam (17.5%) as well as the international infrastructure investment company, Borealis Infrastructure Management Inc. (50%) signed a purchase agreement in respect of Fortum Distribution AB, a company which constitutes Fortum’s electricity network operation in Sweden. 

The total purchase price is EUR 6.6 billion (equivalent to approximately SEK 60.6 billion) on a cash free/debt free basis. Fortum anticipates that the transaction will be completed during the second quarter of 2015, provided that the requisite regulatory approvals and the agreement’s customary conditions are fulfilled. Fortum anticipates reporting a non-recurring revenue item for the second quarter of 2015 of approximately EUR 4.4 billion, equivalent to approximately EUR 5 per share.

Vinge’s team consisted of responsible partner Johan Göthberg together with associates Gustav Jönsson and Andrea Jägerstedt (M&A), partners Jonas Eklund and Carl Johan af Petersens and Fredrik Lundblom as well as associates Emilie Håkansson, Helena Wanhainen and Johan Cederblad (regulatory). 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024